S857 Patient-Reported Outcomes of Response and Remission Following Guselkumab Induction Treatment as Measured by the Inflammatory Bowel Disease Questionnaire: Results Through Week 12 of the Phase 2 GALAXI 1 Study
David T. Rubin(University of California System), Julián Panés(Hospital Clínic de Barcelona), Remo Panaccione(University of Calgary), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Mary Ellen Frustaci(Johnson & Johnson (United States)), Zijiang Yang(Henan Medical University), Silvio Danese(IRCCS Ospedale San Raffaele), Geert D’Haens(Amsterdam University Medical Centers), Kathleen Weisel, Susana Gonzalez, Chenglong Han(Janssen (United States)), Jewel Johanns(Johnson & Johnson (United States)), Matthew Germinaro(Johnson & Johnson (United States))
Cited by 2
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k